American Association for Cancer Research
21598290cd130741-sup-supp_table_4.pdf (108.61 kB)

Supplementary Table S4 from Reduced NF1 Expression Confers Resistance to EGFR Inhibition in Lung Cancer

Download (108.61 kB)
journal contribution
posted on 2023-04-03, 20:41 authored by Elza C. de Bruin, Catherine Cowell, Patricia H. Warne, Ming Jiang, Rebecca E. Saunders, Mary Ann Melnick, Scott Gettinger, Zenta Walther, Anna Wurtz, Guus J. Heynen, Daniëlle A.M. Heideman, Javier Gómez-Román, Almudena García-Castaño, Yixuan Gong, Marc Ladanyi, Harold Varmus, René Bernards, Egbert F. Smit, Katerina Politi, Julian Downward

PDF file 108K, Table S4. Clinical characteristics of human lung adenocarcinoma samples



Activating mutations in the EGF receptor (EGFR) are associated with clinical responsiveness to EGFR tyrosine kinase inhibitors (TKI), such as erlotinib and gefitinib. However, resistance eventually arises, often due to a second EGFR mutation, most commonly T790M. Through a genome-wide siRNA screen in a human lung cancer cell line and analyses of murine mutant EGFR-driven lung adenocarcinomas, we found that erlotinib resistance was associated with reduced expression of neurofibromin, the RAS GTPase-activating protein encoded by the NF1 gene. Erlotinib failed to fully inhibit RAS–ERK signaling when neurofibromin levels were reduced. Treatment of neurofibromin-deficient lung cancers with a MAP–ERK kinase (MEK) inhibitor restored sensitivity to erlotinib. Low levels of NF1 expression were associated with primary and acquired resistance of lung adenocarcinomas to EGFR TKIs in patients. These findings identify a subgroup of patients with EGFR-mutant lung adenocarcinoma who might benefit from combination therapy with EGFR and MEK inhibitors.Significance: The emergence of resistance to EGFR TKIs is a major clinical challenge in the treatment of lung adenocarcinomas driven by mutations in EGFR. This study suggests that, in a subset of patients, resistance is caused by reduced neurofibromin expression, and that in these cases there may be clinical benefit to combining EGFR TKIs with MEK inhibitors. Cancer Discov; 4(5); 606–19. ©2014 AACR.See related commentary by Maertens and Cichowski, p. 519This article is highlighted in the In This Issue feature, p. 495